Dementia diagnosis has long depended on a slow, resource-intensive funnel — cognitive screening in primary care, followed by specialist referral for confirmatory testing. That bottleneck disadvantages patients in rural or underserved areas and delays treatment. Evidence that simple blood tests could meaningfully sharpen diagnosis at the non-specialist level would represent a genuine structural shift in how early Alzheimer's disease is identified and managed.
This cross-sectional analysis drew on the Bio-Hermes dataset, spanning 1,001 participants categorized as cognitively normal (n=417), mild cognitive impairment (MCI, n=312), or probable Alzheimer's disease (PAD, n=272). Researchers evaluated five blood-based biomarkers — amyloid-beta 42/40, phosphorylated-tau 181 (p-tau181), p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) — both individually and as composite panels. These were added to the Mini-Mental State Examination (MMSE) and assessed via receiver operating characteristic (ROC) curves, adjusted for clinically observable covariates and APOE ε4 carrier status. Outcomes included PAD alone, combined MCI-PAD, and both categories further stratified by amyloid positivity confirmed through PET or cerebrospinal fluid.
The significance here lies in the specific amyloid-confirmation angle: identifying individuals whose cognitive impairment is backed by biological evidence of amyloid pathology is precisely the population now eligible for anti-amyloid therapeutics like lecanemab and donanemab. This study's cross-sectional design precludes causal inference and cannot demonstrate whether earlier biomarker-guided triage improves long-term outcomes. The Bio-Hermes cohort was also recruited through memory clinics and research registries, potentially inflating biomarker performance relative to true primary-care populations. Nonetheless, p-tau217 in particular has been converging across multiple independent datasets as a high-performing single marker. Incremental in execution, this analysis is contextually significant given the therapeutic window now opening for amyloid-positive MCI — making accessible, accurate pre-specialist triage a genuinely pressing clinical need.